News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...
Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...
Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...
Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...
The India launch of Eli Lilly's Mounjaro in India has triggered a huge wave of enquiries from those looking for its ...
Meghan Trainor said she’s been taking Mounjaro for weight loss alongside her husband, ‘Spy Kids’ actor Daryl Sabara. The ...
A study found that medicines marketed as Zepbound and Mounjaro can help people lose weight for up to three years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback